成大生物(688739)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
暂无数据
  盈利预测
据成大生物一季报分析:

  盈利能力有所削弱,企业经营效益大幅下降

  成长能力维持稳定,营业收入由亏转盈

  偿债能力维持稳定,偿还流动负债能力很强

  运营能力维持稳定,应收账款周转速度需加快

  现金流能力有所削弱,可持续经营能力转向恶化

  财务数据
    截至2024年第一季度实现净利润0.81亿元,每股收益0.20元。

    截至2024年第一季度最新股东权益966357.81万元,未分配利润412173.41万元。

    截至2024年第一季度最新总资产1010256.17万元,负债43898.36万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入364,709,258.371,750,103,088.241,334,694,071.78871,308,922.37
营业总成本257,814,176.431,103,923,313.7764,513,158.97474,257,967.35
营业利润108,021,869.52577,795,555.86553,213,975.37400,918,281.04
利润总额107,967,047.33576,379,763.58552,054,087.78400,490,310.79
净利润81,463,701.09465,923,566.68463,517,560.88333,611,527.78
其他综合收益----
综合收益总额81,463,701.09465,923,566.68463,517,560.88333,611,527.78
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计7,237,358,260.257,248,921,187.327,303,760,940.347,318,713,498.14
非流动资产合计2,865,203,422.522,832,437,897.872,852,916,232.252,676,143,667.37
资产总计10,102,561,682.7710,081,359,085.1910,156,677,172.599,994,857,165.51
流动负债合计326,104,492.51356,785,829.13357,125,362.25299,259,974.32
非流动负债合计112,879,117.92125,444,016.3128,038,090.75128,789,702.45
负债合计438,983,610.43482,229,845.43485,163,453428,049,676.77
归属于母公司股东权益合计9,663,578,072.349,599,129,239.769,671,513,719.599,566,807,488.74
股东权益合计9,663,578,072.349,599,129,239.769,671,513,719.599,566,807,488.74
负债和股东权益合计10,102,561,682.7710,081,359,085.1910,156,677,172.599,994,857,165.51
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计369,799,852.381,896,391,389.31,314,671,254.74859,421,026.92
经营活动现金流出小计336,547,166.651,219,383,452.25872,201,745.59574,460,569.86
经营活动产生的现金流量净额33,252,685.73677,007,937.05442,469,509.15284,960,457.06
投资活动现金流入小计681,852,222.75,487,096,917.443,551,156,760.761,644,287,718.73
投资活动现金流出小计654,667,027.016,889,380,208.955,336,354,733.053,294,198,490.25
投资活动产生的现金流量净额27,185,195.69-1,402,283,291.51-1,785,197,972.29-1,649,910,771.52
筹资活动现金流入小计----
筹资活动现金流出小计17,577,468.25522,690,789.96445,133,436.18419,720,480.99
筹资活动产生的现金流量净额-17,577,468.25-522,690,789.96-445,133,436.18-419,720,480.99
汇率变动对现金及现金等价物的影响41,736.172,290,411.041,429,541.911,348,305.28
现金及现金等价物净增加额42,902,149.34-1,245,675,733.38-1,786,432,357.41-1,783,322,490.17
期末现金及现金等价物余额4,587,507,490.874,544,605,341.534,003,848,717.54,006,958,584.74
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至2024年第一季度实现净利润0.81亿元,每股收益0.20元。

    截至2024年第一季度最新股东权益966357.81万元,未分配利润412173.41万元。

    截至2024年第一季度最新总资产1010256.17万元,负债43898.36万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入364,709,258.371,750,103,088.241,334,694,071.78871,308,922.37
营业总成本257,814,176.431,103,923,313.7764,513,158.97474,257,967.35
营业利润108,021,869.52577,795,555.86553,213,975.37400,918,281.04
利润总额107,967,047.33576,379,763.58552,054,087.78400,490,310.79
净利润81,463,701.09465,923,566.68463,517,560.88333,611,527.78
其他综合收益----
综合收益总额81,463,701.09465,923,566.68463,517,560.88333,611,527.78
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计7,237,358,260.257,248,921,187.327,303,760,940.347,318,713,498.14
非流动资产合计2,865,203,422.522,832,437,897.872,852,916,232.252,676,143,667.37
资产总计10,102,561,682.7710,081,359,085.1910,156,677,172.599,994,857,165.51
流动负债合计326,104,492.51356,785,829.13357,125,362.25299,259,974.32
非流动负债合计112,879,117.92125,444,016.3128,038,090.75128,789,702.45
负债合计438,983,610.43482,229,845.43485,163,453428,049,676.77
归属于母公司股东权益合计9,663,578,072.349,599,129,239.769,671,513,719.599,566,807,488.74
股东权益合计9,663,578,072.349,599,129,239.769,671,513,719.599,566,807,488.74
负债和股东权益合计10,102,561,682.7710,081,359,085.1910,156,677,172.599,994,857,165.51
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计369,799,852.381,896,391,389.31,314,671,254.74859,421,026.92
经营活动现金流出小计336,547,166.651,219,383,452.25872,201,745.59574,460,569.86
经营活动产生的现金流量净额33,252,685.73677,007,937.05442,469,509.15284,960,457.06
投资活动现金流入小计681,852,222.75,487,096,917.443,551,156,760.761,644,287,718.73
投资活动现金流出小计654,667,027.016,889,380,208.955,336,354,733.053,294,198,490.25
投资活动产生的现金流量净额27,185,195.69-1,402,283,291.51-1,785,197,972.29-1,649,910,771.52
筹资活动现金流入小计----
筹资活动现金流出小计17,577,468.25522,690,789.96445,133,436.18419,720,480.99
筹资活动产生的现金流量净额-17,577,468.25-522,690,789.96-445,133,436.18-419,720,480.99
汇率变动对现金及现金等价物的影响41,736.172,290,411.041,429,541.911,348,305.28
现金及现金等价物净增加额42,902,149.34-1,245,675,733.38-1,786,432,357.41-1,783,322,490.17
期末现金及现金等价物余额4,587,507,490.874,544,605,341.534,003,848,717.54,006,958,584.74
  十大流通股东
十大流通股东 报告期:2024-03-31
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
杨旭660.493.500.00
庄久荣543.532.88543.53
广发证券股份有限公司264.711.40-134.33
刘蕴华251.801.330.00
高军237.001.260.00
阮华凤219.691.16-0.11
王涛209.781.11-20.32
郝建军173.000.92173.00
上海东方证券创新投资有限公司170.000.90170.00
谭水清165.730.88165.73
  主力控盘
  公司简介
成大生物 所属地域: 辽宁省 涉及概念: 流感,沪股通,国企改革,生物疫苗,融资融券
主营业务: 生物药品研究与开发,疫苗生产(具体项目以药品生产许可证为准),货物及技术进出口(国家禁止的品种除外,限制的品种办理许可证后方可经营)。(依法须经批准的项目,经相关部门批准后方可开展经营活动。)
上市日期: 2021-10-28 每股净资产: 23.20元 每股收益: 0.20元 净利润: 0.81亿元 净利润增长率: -35.88%
营业收入: 3.65亿元 每股现金流: 0.08元 每股公积金: 12.09元 每股未分配利润: 9.90元 总股本: 4.16亿 流通股: 1.89亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心